Immutep Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Immutep han disminuido a una tasa media anual de -20.4%, mientras que en la industria Biotechs los beneficios crecieron en un 7.7% anualmente. Los ingresos han ido disminuyendo a una tasa media de 26% al año.

Información clave

-20.4%

Tasa de crecimiento de los beneficios

4.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	-14.6%
Tasa de crecimiento de los ingresos	-26.0%
Rentabilidad financiera	-22.5%
Margen neto	-1,111.9%
Última actualización de beneficios	30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Immutep. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:YP1B Ingresos, gastos y beneficios (AUD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Jun 24	4	-43	9
31 Mar 24	4	-42	9
31 Dec 23	4	-41	9
30 Sep 23	4	-40	9
30 Jun 23	4	-40	9
31 Mar 23	4	-38	8
31 Dec 22	4	-37	7
30 Sep 22	5	-34	7
30 Jun 22	5	-32	7
31 Mar 22	4	-29	7
31 Dec 21	4	-26	7
30 Sep 21	4	-28	7
30 Jun 21	4	-30	6
31 Mar 21	5	-29	6
31 Dec 20	6	-27	6
30 Sep 20	10	-20	6
30 Jun 20	14	-13	6
31 Mar 20	13	-15	6
31 Dec 19	13	-16	6
30 Sep 19	9	-17	6
30 Jun 19	6	-18	6
31 Mar 19	5	-18	6
31 Dec 18	5	-17	7
30 Sep 18	6	-15	7
30 Jun 18	7	-13	7
31 Mar 18	6	-12	7
31 Dec 17	7	-10	6
30 Sep 17	5	-9	5
30 Jun 17	4	-9	4
31 Mar 17	3	-10	5
31 Dec 16	2	-10	5
30 Sep 16	2	-36	30
30 Jun 16	2	-62	54
31 Mar 16	2	-71	54
31 Dec 15	1	-82	54
30 Sep 15	1	-57	30
30 Jun 15	1	-32	6
31 Mar 15	1	-23	5
31 Dec 14	1	-14	5
30 Sep 14	2	-14	5
30 Jun 14	2	-13	4
31 Mar 14	2	-13	4
31 Dec 13	2	-13	5

Ingresos de calidad: YP1B actualmente no es rentable.

Margen de beneficios creciente: YP1B actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: YP1B no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 20.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de YP1B en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: YP1B no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-18.2%).

Rentabilidad financiera

Alta ROE: YP1B tiene una rentabilidad financiera negativa (-22.54%), ya que actualmente no es rentable.

Immutep Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2024 earnings released: AU$0.036 loss per share (vs AU$0.045 loss in FY 2023)

Full year 2023 earnings released: AU$0.045 loss per share (vs AU$0.038 loss in FY 2022)

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022)

Full year 2022 earnings released: AU$0.038 loss per share (vs AU$0.05 loss in FY 2021)

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.034 loss in FY 2020)

Recent updates

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma

Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha

Full year 2024 earnings released: AU$0.036 loss per share (vs AU$0.045 loss in FY 2023)

No longer forecast to breakeven

Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress

Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression

New minor risk - Shareholder dilution

Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial

No longer forecast to breakeven

Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep Limited, Annual General Meeting, Oct 24, 2023

Full year 2023 earnings released: AU$0.045 loss per share (vs AU$0.038 loss in FY 2022)

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Forecast to breakeven in 2026

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

No longer forecast to breakeven

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022)

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Less than half of directors are independent

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

No longer forecast to breakeven

Full year 2022 earnings released: AU$0.038 loss per share (vs AU$0.05 loss in FY 2021)

Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, eftilagimod alpha and IMP76 for the Quarter Ended 30 June 2022

Forecast to breakeven in 2025

Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

High number of new and inexperienced directors

Immutep Limited Announces Executive Changes

Immutep Limited Presents New and Significant Data from the AIPAC Study

Immutep Limited Provides Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2022

Immutep’S Efti in Combination with Msd’S Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2Nd Line Metastatic Lung Cancer Patients

Immutep Limited Announces New Interim Data in 2nd Line Metastatic NSCLC from Its Phase II TACTI-002 Trial

High number of new directors

First half 2022 earnings: EPS in line with expectations, revenues disappoint